The Global. Sandoz, a division of Novartis, has announced the publication of the Egality study in the British Journal of Dermatology, showing that Sandoz's biosimilar etanercept is equivalent to Amgen's original producer Enbrel, in more than 500 adult patients over 52 weeks. The Swiss company ensures that the innovative design of the Egality study includes arms with treatment exchange, in addition to others in which no exchange was made in the products and the patients were treated with the same treatment.